Completion of avicursen (ATL1102) toxicology study
Percheron Therapeutics finalizes nine-month toxicology study for avicursen, paving the way for future clinical trials.
Percheron Therapeutics
Avicursen
Toxicology Study
Stock Market News
Biotechnology
Posted on: 29/09/2024
Read More